Rituximab treatment in pediatric‐onset multiple sclerosis
European Journal of Neurology · 2024-05 · 31 (5)
DOI: 10.1111/ene.16228 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift European Journal of Neurology, online erschienen am 20.02.2024. Verfasst von Markus Breu und 16 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric Pulmonology, Allergology and Endocrinology, Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Vie…. Hauptthemen laut MEDLINE: Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: StratNeuro, Karolinska Institutet, Stiftelsen Sunnerdahls Handikappfond.
Abstract (Originalsprache)
Background and purpose Rituximab (RTX) is frequently used off‐label in multiple sclerosis. However, studies on the risk–benefit profile of RTX in pediatric‐onset multiple sclerosis are scarce.
Methods
In this multicenter retrospective cohort study, patients with pediatric‐onset multiple sclerosis from Sweden, Austria and Germany, who received RTX treatment were identified by chart review. Annualized relapse rates, Expanded Disability Status Scale scores and magnetic resonance imaging parameters (new T2 lesions and contrast‐enhancing lesions) were assessed before and during RTX treatment. The proportion of patients who remained free from clinical and disease activity (NEDA‐3) during RTX treatment was calculated. Side effects such as infusion‐related reactions, infections and laboratory abnormalities were assessed.
Results
Sixty‐one patients received RTX during a median (interquartile range) follow‐up period of 20.9 (35.6) months. The annualized relapse rate decreased from 0.6 (95% confidence interval [CI] 0.38–0.92) to 0.03 (95% CI 0.02–0.14). The annual rate of new T2 lesions decreased from 1.25 (95% CI 0.70–2.48) to 0.08 (95% CI 0.03–0.25) and annual rates of new contrast‐enhancing lesions decreased from 0.86 (95% CI 0.30–3.96) to 0. Overall, 70% of patients displayed no evidence of disease activity (NEDA‐3). Adverse events were observed in 67% of patients. Six patients discontinued treatment due to ongoing disease activity or adverse events.
Conclusion
Our study provides class IV evidence that RTX reduces clinical and radiological activity in pediatric‐onset multiple sclerosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Pediatric Pulmonology, Allergology and Endocrinology, Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Vienna, Austria.
- Neuropediatric Unit, Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.
- Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria.
- Department of Neuroradiology, Karolinska University Hospital, Stockholm, Sweden.
- Department of Clinical Science, Neurosciences, Umeå University, Umeå, Sweden.
- Division of Infectious Diseases, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria.
ORCID-Profile: Markus Breu, Fredrik Sandesjö, Jan Svoboda, Jonatan Salzer, Katharina Fink, Barbara Kornek
Förderung
- StratNeuro
- Karolinska Institutet
- Stiftelsen Sunnerdahls Handikappfond
- Sällskapet Barnavård
- Hjärnfonden
- Region Stockholm
Zitieren
APA
Breu, M., Sandesjö, F., Milos, R. I., Svoboda, J., Salzer, J., Schneider, L., Reichelt, J. B., Bertolini, A., Blaschek, A., Fink, K., Höftberger, R., Lycke, J., Rostásy, K., Seidl, R., Siegert, S., Wickström, R., & Kornek, B. (2024). Rituximab treatment in pediatric‐onset multiple sclerosis. European Journal of Neurology, 31(5). https://doi.org/10.1111/ene.16228
Vancouver
Breu M, Sandesjö F, Milos RI, Svoboda J, Salzer J, Schneider L, et al. Rituximab treatment in pediatric‐onset multiple sclerosis. European Journal of Neurology. 2024;31(5). doi:10.1111/ene.16228
BibTeX
@article{Breu2024,
author = {Breu, Markus and Sandesjö, Fredrik and Milos, Ruxandra-Iulia and Svoboda, Jan and Salzer, Jonatan and Schneider, Lisa and Reichelt, Julian Benedikt and Bertolini, Annikki and Blaschek, Astrid and Fink, Katharina and Höftberger, Romana and Lycke, Jan and Rostásy, Kevin and Seidl, Rainer and Siegert, Sandy and Wickström, Ronny and Kornek, Barbara},
title = {Rituximab treatment in pediatric‐onset multiple sclerosis},
journal = {European Journal of Neurology},
year = {2024},
volume = {31},
number = {5},
doi = {10.1111/ene.16228}
}
EUVIMED